Corcept's Phase 2 DAZALS Study Shows Dazucorilant Provides 87% Reduction in Mortality Risk Over Two Years in ALS Patients
Corcept's Phase 2 DAZALS Study Shows Dazucorilant Provides 87% Reduction in Mortality Risk Over Two Years in ALS Patients